CYBIN INC
Share · CA23256X1006 · CYBN · A2QJAV (XTSE)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of CYBIN INC
No Price
Company Profile for CYBIN INC Share
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Company Data
Name CYBIN INC
Company Cybin Inc.
Symbol CYBN
Website
https://www.cybin.com
Primary Exchange 
TSX
TSX
WKN A2QJAV
ISIN CA23256X1006
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Eric So
Market Capitalization 144 Mio
Country Canada
Currency CAD
Employees 0,1 T
Address 100 King Street West, M5X 1C9 Toronto
IPO Date 2019-09-13
Stock Splits
| Date | Split |
|---|---|
| 19.09.2024 | 1:38 |
| 10.11.2020 | 149:1000 |
Ticker Symbols
| Name | Symbol |
|---|---|
| Frankfurt | R7E1.F |
| NYSE | CYBN |
More Shares
Investors who hold CYBIN INC also have the following shares in their portfolio:
